SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001626199-24-000020
Filing Date
2024-01-05
Accepted
2024-01-05 16:45:51
Documents
13
Period of Report
2024-01-04
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alpn-20240104.htm   iXBRL 8-K 38619
2 EX-10.1 alpn-ex101_20240104.htm EX-10.1 84763
  Complete submission text file 0001626199-24-000020.txt   272554

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alpn-20240104.xsd EX-101.SCH 1953
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alpn-20240104_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alpn-20240104_pre.xml EX-101.PRE 13084
7 EXTRACTED XBRL INSTANCE DOCUMENT alpn-20240104_htm.xml XML 2827
Mailing Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102
Business Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37449 | Film No.: 24516845
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)